39 assets in Intrahepatic Cholangiocarcinoma

Therapeutic assets addressing Intrahepatic Cholangiocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Durvalumab Intrahepatic Cholangiocarcinoma	West China Hospital	P2	BB (65)
Nivolumab Intrahepatic Cholangiocarcinoma	Virogin Biotech Canada Ltd	P2	BB (65)
Cis-Diamminedichloroplatinum Ii Intrahepatic Cholangiocarcinoma	Shanghai 6th People's Hospital	P2	BB (64)
Atezolizumab Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	B (60)
Irinotecan Intrahepatic Cholangiocarcinoma	Tianjin Medical University Cancer Institute and Hospital	P3	B (60)
Ipilimumab Intrahepatic Cholangiocarcinoma	TriSalus Life Sciences, Inc.	P2	B (59)
Fluorouracilum Intrahepatic Cholangiocarcinoma	Tianjin Medical University Cancer Institute and Hospital	P3	B (58)
Lenvatinib Intrahepatic Cholangiocarcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	B (58)
Pembrolizumab Intrahepatic Cholangiocarcinoma	Shanghai 6th People's Hospital	P1/2	B (58)
Oxaliplatin Intrahepatic Cholangiocarcinoma	Sun Yat-sen University	P3	B (56)
Capecitabine Intrahepatic Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc.	P3	CCC (54)
Tinengotinib Intrahepatic Cholangiocarcinoma	TransThera Sciences (Nanjing), Inc.	P3	CCC (54)
Carboplatin Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cobimetinib Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pevonedistat Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
vg161 Intrahepatic Cholangiocarcinoma	Virogin Biotech Canada Ltd	P2	CCC (53)
Adebrelimab Intrahepatic Cholangiocarcinoma	Peking Union Medical College Hospital	P2	CCC (51)
Dexasone Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Donafenib Intrahepatic Cholangiocarcinoma	Sun Yat-sen University	P2	CCC (51)
Floxuridine Intrahepatic Cholangiocarcinoma	Erasmus Medical Center	P2	CCC (51)
pds01adc Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Pucotenlimab Intrahepatic Cholangiocarcinoma	Sun Yat-sen University	P2	CCC (51)
Regorafenib Intrahepatic Cholangiocarcinoma	Shanghai Zhongshan Hospital	P2	CCC (51)
Rilvegostomig Intrahepatic Cholangiocarcinoma	Federation Francophone de Cancerologie Digestive	P2	CCC (51)
Rivoceranib Intrahepatic Cholangiocarcinoma	Peking Union Medical College Hospital	P2	CCC (51)
Toripalimab Intrahepatic Cholangiocarcinoma	Shanghai Zhongshan Hospital	P2	CCC (51)
Certepetide Intrahepatic Cholangiocarcinoma	Lisata Therapeutics, Inc.	P2	CCC (49)
PCV 13 Intrahepatic Cholangiocarcinoma	Mayo Clinic	P1/2	CCC (48)
Ale.P03 Intrahepatic Cholangiocarcinoma	Alentis Therapeutics AG	P1/2	CC (47)
Nelitolimod Intrahepatic Cholangiocarcinoma	TriSalus Life Sciences, Inc.	P1/2	CC (46)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Intrahepatic Cholangiocarcinoma	National Cancer Institute (NCI)	P2	CC (44)
Celecoxib Intrahepatic Cholangiocarcinoma	Shanghai 6th People's Hospital	P1/2	CC (43)
cgt4859 Intrahepatic Cholangiocarcinoma	Cogent Biosciences, Inc.	P1/2	CC (43)
Guadecitabine Intrahepatic Cholangiocarcinoma	University of Southern California	P1	CC (43)
Kin-3248 Intrahepatic Cholangiocarcinoma	Kinnate Biopharma	P1	CC (43)
Tyra-200 Intrahepatic Cholangiocarcinoma	Tyra Biosciences, Inc	P1	CC (43)
Hmpl-453 Intrahepatic Cholangiocarcinoma	Hutchmed	P2/3	NR ()